Semma Therapeutics
ClosedCambridge, United States · Founded 2014
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2014
- Business Model
- B2B
- Website
- semmatherapeutics.com
- Last Round
- Series BNov 2017
- Rounds
- 2
About
Semma Therapeutics was a Cambridge, Massachusetts-based biotechnology company founded in 2014 by Harvard stem cell biologist Douglas Melton. The company pioneered the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes. Semma raised $158 million before being acquired by Vertex Pharmaceuticals in 2019 for $950 million.
Summary
Semma Therapeutics is a Biotech company based in Cambridge, United States, founded in 2014. Its most recent funding was a Series B round in Nov 2017. Investors include MPM Capital, Vertex Pharmaceuticals and Eight Roads Ventures.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Sep 2019
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
MPM Capital
2 rounds
Vertex Pharmaceuticals
1 round
Eight Roads Ventures
1 round
Cowen Healthcare Investments
1 round
ARCH Venture Partners
2 rounds
Medtronic
2 rounds
F-Prime Capital
1 round
Novartis
1 round
SinoPharm
1 round
ORI Healthcare Fund
1 round
Wu Capital
1 round
6 Dimensions Capital
1 round
Fidelity Biosciences
1 round
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...